# Continuous Renal Replacement {#sec-crrt}

Form of extracorporeal blood purification using a continuous circuit, providing:

:::column-margin
This covers CRRT; a general overview and comparison of RRT modalities is provided under @sec-rrt.
:::

* Continuous control of:
	* Fluid status
	* Acid-base status
	* Electrolyte balance
	* Intracerebral water
* Good haemodynamic stability
* Minimal infective risk
* Facilitation of **renal recovery**

## Principles

{{< include /includes/rrt_principles.qmd >}}

:::column-margin
CRRT relies on the same physical principles as IHD and SLED, but as fluid shifts occur more slowly CRRT has greater haemodynamic stability either.\
\
Consequently, CRRT is preferred in patients with:

* Haemodynamic instability
* High ICPs, brain oedema
:::


### Types of CRRT

There are a number of technical variations of CRRT based on the physical principles used:

* **Haemofiltration**\
No dialysate is used.
	* Ultrafiltration results in a solute-water mix filtered across the semi-permeable membrane\
	* A substitution solution is used to replace lost volume\
	The difference between the ultrafiltration volume produced and the substitution solution infused is the fluid removal.
* **Haemodialysis**\
Counter-current delivery of dialysis solution.
	* Clearance is almost entirely by diffusion
* **Haemodiafiltration**\
Combination of:
	* Counter-current dialysis solution\
	Solute clearance by diffusion.
	* Ultrafiltration\
	Additional substitution solution used to replace lost volume.


## Indications

Indications for CRRT include:

:::column-margin
CRRT may be initiated in ICU based on anticipation of reaching these thresholds, or on a series of composite features that individually do not meet the threshold.
:::

* Established renal failure
* Volume overload\
With oliguria/anuria.
* Solute
	* Urea >35mmol/L
	* Uraemic complications
	* Hyperkalaemia
	* Hyponatraemia <110mmol/L
	* Hypernatraemia >160mmol/L
* Other
	* Dialysable toxin
	* Hyperthermia >40°C


## Contraindications

## Equipment

Vascular dialysis catheter:

* Uncuffed, non-tunnelled catheter
* Preferentially sited in:
	* Right IJV
	* Femoral vin
	* Left IJV
	* Dominant SCV\
	Risk of central vein stenosis with SCV insertion.
	* Non-dominant SCV
* Positioned at the junction of the SCV and RA
	* Risk of atrial erosion if in too far
	* Risk of central vein stenosis if abutting SVC 


Solutions:

* Dialysate
	* Bicarbonate solutions are preferred over lactate solutions, *especially* in:
		* Shock
		* Hepatic failure
		* Lactic acidosis


## Technique

Clinician-adjustable values in CRRT include:

* Dose\
Effluent production in mL/kg/hr.
	* CRRT dose should be 20-25mL/hr\
	This typically requires a prescription of 25-30mL/hr due to interruptions.
	* Hypotension and electrolyte disturbances are more common at higher intensities (dosing) and are not associated with improved outcome


## Anticoagulation

Anticoagulation is frequently used to prevent clotting of the filter and circuit, but must be balanced against risks of bleeding. In general, circuit anticoagulation is recommended when patient is:

* Not coagulopathic
* Not systemically anticoagulated


:::column-margin
Acceptable filter life is ~24 hours.
:::

: Comparison of Anticoagulation Techniques

+-------------------------------------------------+---------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+
| Technique                                       | Method                                                                                      | Advantages                                                                                  | Disadvantages                                                              |
+=================================================+=============================================================================================+=============================================================================================+============================================================================+
| No anticoagulant                                |                                                                                             | * Used in patients with endogenous coagulopathy or other contraindication                   | * ↓ Filter life                                                            |
+-------------------------------------------------+---------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+
| Heparin alone                                   | * Low dose\                                                                                 | * Easy, cheap, familiar, available                                                          | * HITTS                                                                    |
|                                                 | Heparin <500 units/hr.                                                                      | * Minimal effect on systemic coagulation                                                    | * Heparin resistance                                                       |
|                                                 | * Medium dose\                                                                              | * Therapeutic heparinisation can be used if systemic anticoagulation is indicated (e.g. PE) |                                                                            |
|                                                 | Heparin 500-1000 units/hr.                                                                  |                                                                                             |                                                                            |
+-------------------------------------------------+---------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+
| Regional anticoagulation with citrate           | Citrate given into the access line and reversed with calcium given into the return line.    | * Regional anticoagulation reduces systemic haemorrhage                                     | * Special dialysate required                                               |
|                                                 |                                                                                             | * Longer filter life                                                                        | * Citrate toxicity (especially hepatic failure, shock)\                    |
|                                                 |                                                                                             | * ↓ Transfusion and major bleeding compared to UFH                                          | Metabolic acidosis, hypocalcaemia, widening total calcium:ionised calcium. |
+-------------------------------------------------+---------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+
| Regional anticoagulation with heparin/protamine | Heparin into access line and reversed with protamine at a fixed ratio into the return line. | * Easy, cheap, familiar, available                                                          | * HITTS                                                                    |
|                                                 |                                                                                             | * Reversible                                                                                | * Heparin resistance                                                       |
|                                                 |                                                                                             | * Can be monitored                                                                          | * Narrow TI                                                                |
|                                                 |                                                                                             | * Short half-life                                                                           | * Unpredictable kinetics                                                   |
+-------------------------------------------------+---------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+
| Systemic low-molecular weight heparin           |                                                                                             | * Predictable kinetics                                                                      | * May accumulate in renal failure                                          |
|                                                 |                                                                                             | * Does not require monitoring                                                               | * Requires anti-Xa for monitoring                                          |
|                                                 |                                                                                             | * Less HITTS                                                                                | * Incompletely reversed with protamine                                     |
|                                                 |                                                                                             |                                                                                             | * More expensive                                                           |
+-------------------------------------------------+---------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+


### Responding to Filter Clotting

* Evaluate for mechanical causes\
Cannula:
	* Position
	* Flow rates
	* Kinking
* Check anticoagulation efficacy
* Consider ↑ or change of anticoagulation

## Complications

* Vascular access
* Haemodynamic instability\
More pronounced with more aggressive dialysis modes (particularly IHD).


---

## References

1. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. [KDIGO Clinical Practice Guideline for Acute Kidney Injury](http://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf). Kidney inter., Suppl. 2012; 2: 1–138.
1. Bersten, A. D., & Handy, J. M. (2018). Oh’s Intensive Care Manual. Elsevier Gezondheidszorg.